The first commercial AI application case in Zhejiang province defines legal limits on generative tools; CFIUS blocked more transactions last year than in previous years amid rising China tensions; and Fintech companies rush to raise equity for stablecoin activity in Hong Kong.
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
Hainan launches pilot program expanding financial products access to foreigners; Chinese companies reconsider pivot to Southeast Asia as region targeted by U.S. tariffs; and Chinese regulator puts U.S. outbound investments on hold.
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
The CSRC has not approved U.S. IPOs since April despite a small-cap listing rebound earlier; New arbitration rules emphasize party consent, tribunal independence, and risk management in AI use; and Record-high investments in Belt and Road Initiative driven by strategic sectors.
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
